Literature DB >> 14534877

The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.

Chih-Hsiung Kang1, Tsan-Jung Yu, Hwei-Ho Hsieh, Joseph W Yang, Kenneth Shu, Chao-Cheng Huang, Po-Huang Chiang, Yow-Ling Shiue.   

Abstract

BACKGROUND: Contralateral, metachronous upper urinary tract (UUT) tumors after primary transitional cell carcinoma (TCC) of the UUT are reported rarely, and to the authors' knowledge the risk factors have not been determined to date. In addition, few reports have described the characteristics of recurrent bladder tumors and contralateral UUT tumors and any relation between theses tumor types.
METHODS: Statistical analysis of data from 223 patients with documented primary UUT-TCC was undertaken. After excluding bilateral involvement and distant metastases, 12 variables were analyzed by multivariate analysis in 189 patients to determine the risk factors for recurrent urothelial tumors.
RESULTS: The incidence rates of recurrent bladder tumors and contralateral UUT tumors were 31.2% and 5.8%, respectively. Multiplicity was determined as a risk factor for recurrent bladder tumors. Renal insufficiency, uremia, and concurrent bladder tumors significantly predisposed patients to develop contralateral UUT tumors after primary UUT-TCC. The time intervals and stage distributions differed significantly between recurrent bladder tumors and contralateral UTT tumors. Patients who had recurrent bladder tumors had earlier stage tumors and had a shorter time to recur compared with patients who had contralateral, metachronous UUT tumors.
CONCLUSIONS: For patients with primary UUT-TCC, regular follow-up by cystoscopy is necessary to detect recurrent bladder tumors. Intravenous urography or retrograde pyelography should be performed for patients who have a high risk of developing contralateral UUT tumors. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 14534877     DOI: 10.1002/cncr.11691

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma.

Authors:  Shu-Fen Tseng; Yao-Chi Chuang; Wen-Chou Yang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

2.  Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.

Authors:  Chien-Hsu Chen; Mu-Yao Tsai; Ping-Chia Chiang; Ming-Tse Sung; Hao-Lun Luo; Jau-Ling Suen; Eing-Mei Tsai; Po-Hui Chiang
Journal:  Cancer Immunol Immunother       Date:  2021-03-19       Impact factor: 6.968

3.  Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.

Authors:  Dong Fang; Lei Zhang; Xuesong Li; Gengyan Xiong; Xiaopeng Chen; Wenke Han; Zhisong He; Liqun Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-28       Impact factor: 4.553

4.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

5.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival.

Authors:  Bogomir Milojevic; Milan Djokic; Sandra Sipetic-Grujicic; Dragica Milenkovic-Petronic; Aleksandar Vuksanovic; Dejan Dragicevic; Uros Bumbasirevic; Cane Tulic
Journal:  Int Urol Nephrol       Date:  2011-02-26       Impact factor: 2.370

6.  Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma.

Authors:  Marco Cosentino; Joan Palou; Josep M Gaya; Alberto Breda; Oscar Rodriguez-Faba; Humberto Villavicencio-Mavrich
Journal:  World J Urol       Date:  2012-05-03       Impact factor: 4.226

7.  Long-term outcomes of complete urinary tract exenteration for dialysis patients with urothelial cancer.

Authors:  Chien-Hui Ou; Wen-Horng Yang
Journal:  Int Urol Nephrol       Date:  2017-02-04       Impact factor: 2.370

Review 8.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

9.  Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis.

Authors:  S-L Liu; L Qi; W-Q Han; B-S Zhu; X Zhou; S-S Jiang; M-F Chen; Y Li; W He; L-F Liu; X-H Hu; Y Xie; F-H Zeng; X-B Zu
Journal:  Clin Transl Oncol       Date:  2015-07-29       Impact factor: 3.405

10.  Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.

Authors:  Chia-En Li; Chia-Shen Chien; Yao-Chi Chuang; Ye-In Chang; Hsiu-Pei Tang; Chih-Hsiung Kang
Journal:  Int Urol Nephrol       Date:  2016-03-19       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.